All data are based on the daily closing price as of July 18, 2025
k

Kaken Pharmaceutical

4521.TSE
25.91 USD
0.02
+0.08%

Overview

Last close
25.91 usd
Market cap
980.96M usd
52 week high
32.47 usd
52 week low
21.11 usd
Target price
30.91 usd

Valuation

P/E
10.5373
Forward P/E
N/A
Price/Sales
1.5503
Price/Book Value
0.9551
Enterprise Value
534.47M usd
EV/Revenue
0.8459
EV/EBITDA
3.6129

Key financials

Revenue TTM
631.83M usd
Gross Profit TTM
393.29M usd
EBITDA TTM
158.50M usd
Earnings per Share
2.45 usd
Dividend
1.01 usd
Total assets
1.28B usd
Net debt
-337.00M usd

About

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective next-generation oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
  • Symbol
    4521.TSE
  • Exchange
    TSE
  • Isin
    JP3207000005
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Tomoyuki Koseki
  • Headquarter
    Tokyo
  • Web site
    https://www.kaken.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top